90 related articles for article (PubMed ID: 1337189)
21. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
22. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
[TBL] [Abstract][Full Text] [Related]
23. Antiproteinuric effect of angiotensin-converting enzyme inhibition and C5b-9 urinary excretion in membranous glomerulonephritis.
Praga M; Paz Artal E; Hernández E; Segura J; Moreno MA; Morales JM; Rodicio JL
Nephrol Dial Transplant; 1997 Dec; 12(12):2576-9. PubMed ID: 9430854
[TBL] [Abstract][Full Text] [Related]
24. Membranous glomerulopathy associated with idiopathic hypereosinophilic syndrome.
Frigui M; Hmida MB; Jallouli M; Kechaou M; Frikha F; Bahloul Z
Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):320-2. PubMed ID: 20228521
[TBL] [Abstract][Full Text] [Related]
25. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting the long-term outcomes of idiopathic membranous nephropathy.
Huh H; Lee H; Lee JP; Kim DK; Oh S; Oh YK; Kim YS; Lim CS
BMC Nephrol; 2017 Mar; 18(1):104. PubMed ID: 28347297
[TBL] [Abstract][Full Text] [Related]
27. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria.
Praga M; Hernández E; Montoyo C; Andrés A; Ruilope LM; Rodicio JL
Am J Kidney Dis; 1992 Sep; 20(3):240-8. PubMed ID: 1519604
[TBL] [Abstract][Full Text] [Related]
28. Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action.
Heeg JE; de Jong PE; de Zeeuw D
Clin Sci (Lond); 1991 Sep; 81(3):367-72. PubMed ID: 1655338
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of membranous glomerulonephritis: analysis of data from the Italian Renal Biopsy Registry].
Garozzo M; Puliatti D; Battaglia GG
G Ital Nefrol; 2011; 28(4):425-30. PubMed ID: 21809312
[TBL] [Abstract][Full Text] [Related]
30. Nonimmunosuppressive therapy of membranous nephropathy.
Schieppati A; Ruggenenti P; Perna A; Remuzzi G
Semin Nephrol; 2003 Jul; 23(4):333-9. PubMed ID: 12923721
[TBL] [Abstract][Full Text] [Related]
31. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease.
Gansevoort RT; de Zeeuw D; de Jong PE
Nephrol Dial Transplant; 1995; 10(4):497-504. PubMed ID: 7623991
[TBL] [Abstract][Full Text] [Related]
32. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis.
Odabas AR; Cetinkaya R; Selcuk Y; Bilen H
Ups J Med Sci; 2001; 106(3):183-8. PubMed ID: 12166510
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis.
Williams PS; Bone JM
Nephrol Dial Transplant; 1989; 4(3):181-6. PubMed ID: 2498775
[TBL] [Abstract][Full Text] [Related]
34. [A case of significant natriuresis and improvement of proteinuria by Temocapril, an ACE inhibitor with biliary excretion, in loop diuretics resistant edema in membranous nephropathy].
Takeda T; Shirakawa K; Nogaki F; Kamata T; Suyama K; Ono T; Muso E; Sasayama S
Nihon Jinzo Gakkai Shi; 1999 Dec; 41(8):813-7. PubMed ID: 10655730
[TBL] [Abstract][Full Text] [Related]
35. Proteinuria in Frasier syndrome.
Peco-Antić A; Ozaltin F; Parezanović V; Milosevski-Lomić G; Zdravković V
Srp Arh Celok Lek; 2013; 141(9-10):685-8. PubMed ID: 24364235
[TBL] [Abstract][Full Text] [Related]
36. [A case of hepatitis C virus associated membranous glomerulonephritis ameliorated by corticosteroid therapy].
Kurihara I; Saito T; Nakayama K; Yusa A; Soma J; Sato H; Ito S
Nihon Jinzo Gakkai Shi; 1998 May; 40(4):290-4. PubMed ID: 9654913
[TBL] [Abstract][Full Text] [Related]
37. Antiproteinuric effect of angiotensin-converting-enzyme inhibitors in patients with primary glomerular disease and normal renal function.
Fabbri A; Cocchi R; Degli Esposti E; Lucatello A; Sturani A; Tampieri G; Fusaroli M
Nephrol Dial Transplant; 1990; 5 Suppl 1():81-3. PubMed ID: 2129469
[TBL] [Abstract][Full Text] [Related]
38. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease.
Gansevoort RT; de Zeeuw D; de Jong PE
Am J Kidney Dis; 1993 Jul; 22(1):202-6. PubMed ID: 8322784
[TBL] [Abstract][Full Text] [Related]
39. Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease.
Navis G; Buter H; de Jong PE; Dullaart RP; de Zeeuw D
Contrib Nephrol; 1997; 120():88-96. PubMed ID: 9257051
[No Abstract] [Full Text] [Related]
40. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition.
Praga M; Borstein B; Andres A; Arenas J; Oliet A; Montoyo C; Ruilope LM; Rodicio JL
Am J Kidney Dis; 1991 Mar; 17(3):330-8. PubMed ID: 1996578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
